Scarica l'app Stockscreener
1.10
1.79%
-0.02
Dopo l'orario di chiusura:
1.10
Precedente Chiudi:
$1.12
Aprire:
$1.11
Volume 24 ore:
725.33K
Relative Volume:
0.61
Capitalizzazione di mercato:
$119.01M
Reddito:
$4.35M
Utile/perdita netta:
$-45.53M
Rapporto P/E:
-1.0185
EPS:
-1.08
Flusso di cassa netto:
$-44.79M
1 W Prestazione:
-3.51%
1M Prestazione:
-7.56%
6M Prestazione:
+22.36%
1 anno Prestazione:
+29.41%
Intervallo 1D:
$1.095
$1.135
Intervallo di 1 settimana:
$1.08
$1.175
Portata 52W:
$0.7201
$1.80
Lucid Diagnostics Inc Stock (LUCD) Company Profile
Nome
Lucid Diagnostics Inc
Settore
Industria
Telefono
212 949 4319
Indirizzo
360 MADISON AVENUE, NEW YORK
Confronta LUCD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LUCD
Lucid Diagnostics Inc
|
1.10 | 121.18M | 4.35M | -45.53M | -44.79M | -1.08 |
|
ABT
Abbott Laboratories
|
125.64 | 218.92B | 43.11B | 13.98B | 6.66B | 7.98 |
|
BSX
Boston Scientific Corp
|
106.21 | 152.62B | 17.55B | 2.03B | 2.72B | 1.37 |
|
SYK
Stryker Corp
|
396.66 | 153.22B | 23.22B | 2.86B | 3.58B | 7.40 |
|
MDT
Medtronic Plc
|
92.32 | 117.89B | 33.54B | 4.66B | 5.19B | 3.62 |
|
EW
Edwards Lifesciences Corp
|
75.80 | 45.12B | 5.54B | 4.18B | 623.10M | 7.00 |
Lucid Diagnostics Inc Stock (LUCD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2021-12-27 | Iniziato | Ascendiant Capital Markets | Buy |
| 2021-11-08 | Iniziato | BTIG Research | Buy |
| 2021-11-08 | Iniziato | Cantor Fitzgerald | Overweight |
| 2021-11-08 | Iniziato | Needham | Buy |
Lucid Diagnostics Inc Borsa (LUCD) Ultime notizie
What drives Lucid Diagnostics Inc. stock priceFree Advanced Stock Screener Access - Autocar Professional
Is Lucid Diagnostics Inc. a good long term investmentStrong return on assets - jammulinksnews.com
Lucid Diagnostics Inc. Stock Analysis and ForecastBreakthrough capital growth - jammulinksnews.com
What analysts say about Lucid Diagnostics Inc. stockSpectacular growth rates - jammulinksnews.com
Immunovia's Strategic Hiring of Natalie Carfora: A Catalyst for Reimbursement Success and Market Expansion of PancreaSure - AInvest
Immunovia Names Natalie Carfora VP of Market Access and Reimbursement Ahead of PancreaSure Launch - AInvest
[New] Lucid Stock Price Prediction 2024, 2025 To 2050 - Exla Resources
Lucid says meeting scheduled to determine Medicare coverage for cancer test - MSN
LUCD’s 2025 Market Dance: Up 26.00% – Time to Invest? - investchronicle.com
what makes lucid diagnostics inc. stock price move sharply3x Growth Potential - Newser
Esophageal Cancer Detection Revolution: Lucid's Medicare Milestone and Its Market Impact - AInvest
Lucid says AdCom meeting set to determine cancer test coverage - Seeking Alpha
Lucid Diagnostics Inc. shares fall 5.98% intraday as MolDX convenes expert medical panel on Medicare. - AInvest
MolDX to Convene Expert Medical Panel on Medicare Local Coverage Determination (LCD) for Lucid Diagnostics' EsoGuard® Esophageal DNA Test - StreetInsider
How Lucid Diagnostics Inc. stock performs during market volatilityRisk Managed Trading Strategy - Newser
What makes Lucid Diagnostics Inc. stock price move sharplyInvestor Favorite Picks - Newser
Why Lucid Diagnostics Inc. stock attracts strong analyst attentionRisk Aware High Growth Picks - Newser
Brokerages Set Lucid Diagnostics Inc. (NASDAQ:LUCD) Price Target at $3.55 - Defense World
Lucid Diagnostics Inc.(NasdaqCM: LUCD) added to Russell Small Cap Comp Growth Index - MarketScreener
Lucid Diagnostics Inc.(NasdaqCM: LUCD) added to Russell 3000 Index - MarketScreener
Is Lucid Diagnostics, Inc. technically bullish or bearish? - MarketsMojo
Major California Health System Launches Comprehensive Esophageal Precancer Testing Program Using Lucid Diagnostics' EsoGuard® Esophageal DNA Test - BioSpace
Lucid Diagnostics Holds Annual Stockholders Meeting - TipRanks
Leading California Hospital Network Launches Revolutionary 3-Minute Cancer Detection Test from Lucid Diagnostics - Stock Titan
119,887 Shares in Lucid Diagnostics Inc. (NASDAQ:LUCD) Acquired by Citadel Advisors LLC - Defense World
Ascendiant Capital Markets Issues Positive Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price - Defense World
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 By Investing.com - Investing.com South Africa
Ascendiant Capital raises Lucid Diagnostics stock price target to $7.75 - Investing.com Australia
Lucid Diagnostics (LUCD) Stock Maintained at Buy by Ascendiant Capital | LUCD Stock News - GuruFocus
Lucid Diagnostics (LUCD) Target Price Increased by Ascendiant | - GuruFocus
Lucid Diagnostics Files For Offering Of 36 Million Shares Of Common Stock - MarketScreener
Pavmed's Veris Health Signs Long-Term Partnership Deal With Ohio State University Hospital - marketscreener.com
SAIC, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Lucid Diagnostics Enters $25M Sales Agreement - TipRanks
Lucid Diagnostics joins Russell 2000 and 3000 indexes - Mugglehead Magazine
Lucid Diagnostics to Join Russell 2000® and Russell 3000® Indexes - The Malaysian Reserve
Lucid Diagnostics to Join Russell 2000, Russell 3000 Indexes - marketscreener.com
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes By Investing.com - Investing.com South Africa
Lucid Diagnostics to join Russell 2000 and Russell 3000 indexes - Investing.com Australia
Lucid Diagnostics Inc Azioni (LUCD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.03%
0.79%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):